Abstract 214P
Background
Urothelial carcinoma (UC), including upper tract UC (UTUC) and UC of the bladder (UCB), is one of the most common malignancies worldwide. The current standard methods for diagnosis and monitoring of UC are often invasive and/or lack sensitivity and specificity. Emerging evidence has shown that urinary RNAs could potentially serve as promising biomarkers for UC diagnosis. In this study, we intended to develop and validate an accurate and noninvasive urine RNA test for UC diagnosis and monitoring.
Methods
Gene expression profiling of our previously reported 32 RNA targets were analyzed TaqMan qPCR arrays. We pooled all samples analyzed before to obtain a larger training set and develop a diagnostic gene panel. The identified gene panel was then validated in a large-scale independent cohort of 752 patients. Voided urine specimens were prospectively collected at 3 hospitals from subjects scheduled for tumor surgery or endoscopy for the urinary tract due to suspicious symptoms. The sensitivity and specificity of the gene panel were evaluated using endoscopy and/or histologic diagnosis as a reference.
Results
An eight-gene panel (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2 and SWINGN) was developed. In the prospective cohort, the gene panel achieved 93.4%overall accuracy (702/752), 92.3% sensitivity (275/298) and 94.1% specificity (427/454). High sensitivity was maintained in low grade (89.9%, 62/69), early stage (88.5%, 115/130) and residual tumors (89.5%, 34/38). Notably, the gene panel accurately detected UTUCs with 97.3% (36/37) sensitivity, indicating that urinary RNA targets selected here were relevant markers for both UTUC and UCB. Besides, the specificity among other malignancies like prostate cancer, renal cancer, etc. reached 94.5% (173/183). With respect to surveillance, the gene panel showed 88.6% sensitivity and 98.2% specificity for detecting recurrences in 136 patients.
Conclusions
In summary, the eight-gene urine test showed superior sensitivity and specificity for diagnosis of UCs across all tumor stages, grades and sites, hence might represent a promising tool for noninvasive UC detection and surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Canhelp Genomics.
Disclosure
Y. Wo, Z. Luo, J. Chen, Q. Xu: Financial Interests, Personal, Full or part-time Employment: Canhelp Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract